All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec004}
============

Leishmaniases are vector-borne infections caused by protozoa of genus *Leishmania*, affecting mammals. More than 30 *Leishmania* species are recognized, of which 20 are considered infective for humans and other mammals \[[@pntd.0007981.ref001]\]. The ability to distinguish between *Leishmania* species is crucial for differentiation of the different clinical manifestations of the disease (visceral, cutaneous or mucocutaneus) to establish correct diagnosis and prognosis of the disease as well as to support decision-making regarding administration of the appropriate treatment. The rapid and accurate diagnosis of cutaneous leishmaniasis (CL) and the identification of the species involved in the infection are crucial for the therapeutic regimen and control of the disease.

The diagnosis of CL is based on the detection of the parasite in the sample collected directly from the patient´s lesions. The methods include direct microscope test, culture of aspirates and histopathology biopsies. Although the specificity of these methods is high, varying from 86% \[[@pntd.0007981.ref001]\] to 100% \[[@pntd.0007981.ref002]\], they have important drawbacks mainly related to their sensitivity and time consuming due to the high subjective component.

The direct test's sensitivity can vary depending of the type of tissue where the sample is collected, amount of sample obtained, as well as the technique used for the sampling and processing. The evolution time of the lesion and the previous use of treatments may also interfere with the sensitivity of the direct methods \[[@pntd.0007981.ref003]\]. For all these reasons the sensitivity reported varies from 78.3% to 90.4% in samples taken from the active edge of the lesion *vs*. the base of the ulcer, respectively \[[@pntd.0007981.ref004]\]. However, other studies have reported sensitivities as low as 32.7% and 37% in samples from the active edge of the lesion \[[@pntd.0007981.ref005],[@pntd.0007981.ref006]\]. On the other hand, the culture-based and histopathology test has lower sensitivity than direct test and therefore they do not have an important role in the diagnosis of CL \[[@pntd.0007981.ref003]\]. The inaccuracies in diagnosis prevent timely access to treatment and the establishment of guided strategies for the control and reduction of morbidity for leishmaniasis, affecting finally the patient welfare.

To overcome these drawbacks, different molecular tests are proposed for the diagnosis of CL by detecting the parasite genetic material (DNA or RNA), to improve (contrast) the accuracy of the traditional microscopic-based parasitological diagnosis. These molecular techniques include multilocus enzyme electrophoresis (MLEE), conventional polymerase chain reaction (PCR) based assays, quantitative Real Time PCR or simplified PCR methods. In addition, available tools for species identification and phylogenetic analysis include DNA sequencing analysis, restriction fragment length polymorphism (RFLP) analysis, and PCR-fingerprinting techniques as well as novel methods such as multilocus sequence typing (MLST) and multi‐ locus microsatellite typing (MLMT).

The PCR based assays, are rapid, sensitive and discriminative at species or even strain level. They offer high flexibility and utility together with its sensitivity and specificity. Nevertheless, the complexity and cost are limiting factors for its routine application in clinics, restricting its use to research laboratory environments. However, there is an urgent need for standardization, optimization and simplification of PCR based applications to be used mainly in endemic areas around the world which will have an impact in disease control.

Providing clear evidence on the diagnostic accuracy of molecular tests allows to clarify the role of molecular techniques in epidemiological contexts. Here the importance of knowing the diagnostic accuracy of molecular tests so that public health institutions and those in charge of making decisions may implement the use of theses test for the control of CL. Based on the hypothesis that the PCR-based molecular tools are the most accurate diagnostic method, the objective of this systematic review was to assess the diagnostic attributes of PCR-based molecular tools in a meta-analysis of the published literature, with the purpose of contribute to the improvement of CL control.

Methods {#sec005}
=======

The review protocol was registered on PROSPERO 2017 and is available from: <http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017055859>. This systematic literature review was performed based on recommendations by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@pntd.0007981.ref007]\].

Study scope and definition of the reference standard {#sec006}
----------------------------------------------------

This systematic review answers the question: what is the accuracy of the PCR-based methods in the diagnosis of CL in patients with potential infection attending health care services in endemic areas? For this purpose, the reference standard was defined as a compatible clinical lesion in addition to the demonstration of amastigotes through direct microscopic test or in combination with culture isolation of *Leishmania* parasites from lesion material. Other types of composite reference standards were not included. The confirmatory diagnostic of LC was based on the observation of intra- or extracellular *Leishmania* amastigotes through direct microscopic observation and/or promastigote isolation in cultures media.

Literature search {#sec007}
-----------------

To identify all relevant studies, we performed an electronic search using key terms in the following databases: PubMed, EMBASE and LILACS. These databases were selected because of their coverage of the literature and because we believe they will provide a representative sample of the published studies of diagnostic molecular tests from January 1990 to December 2018. In February 2019, The following MeSH terms were generated: "((((((((((((\"Leishmaniasis, Cutaneous\") OR \"Leishmaniasis, Diffuse Cutaneous\")) OR (\"cutaneous leishmaniasis\" OR \"diffuse cutaneous leishmaniasis\" OR \"skin leishmaniasis\"))) AND ((\"Polymerase Chain Reaction\") OR (\"Polymerase chain reaction\" OR PCR))))) AND ((((((((\"Sensitivity and Specificity\") OR \"Sensitivity and Specificity/standards\")) OR (\"sensitivity OR specificity\" OR \"sensitivity OR specificity/standards\" OR \"sensitivity\" OR \"specificity\"))) OR (screening OR \"false positive\" OR \"false negative\" OR accuracy)) OR ((((\"Predictive Value of Tests\") OR \"Predictive Value of Tests/standards\")) OR (\"Predictive Value of Tests\" OR \"Predictive Value of Tests/standards\" OR \"predictive value\" OR \"predictive values of tests\" OR \"reference value\" OR \"references values\"))) OR ((\"ROC Curve\") OR (\"ROC Curve\" OR ROC \"Receiver operating characteristics\" OR \"roc analysis\" OR \"roc analyses\" OR \"ROC and\" OR \"ROC area\" OR \"ROC auc\" OR \"ROC characteristics\" OR \"ROC curve method\" OR \"ROC curves\" OR \"ROC estimated\" OR \"ROC evaluation\" OR \"ROC likelihood ratio\"))))) AND (\"direct exam\" OR \"direct test\" OR \"direct tests\" OR \"direct microscopy\" OR smear)) AND Humans). The limitations were the language (English/Spanish) and publication date (from 1990/01/01 to 2018/12/31), the search was limited to that period because it corresponds with the period where most of the molecular tests were developed. The search was also limited to those studies performed in humans.

Inclusion criteria {#sec008}
------------------

In this review only prospective cohort studies were included (meaning, those studies including patients consecutively recruited, and those where all patients were submitted to the index test and the reference test), retrospective and cross-sectional studies; in some studies, re-counts of the same patients were performed to analyze different diagnostic techniques based on PCR ([Table 1](#pntd.0007981.t001){ref-type="table"}). All studies met the following criteria: (i) patients with clinical suspicion of cutaneous leishmaniasis, (ii) use of the molecular test for the diagnosis of CL, (iii) use of clinical samples isolated from humans, (iv) comparison with the reference standard "direct microscopic test alone or in combination with culture", (v) capacity of completion of a 2x2 contingency table. Those studies with patients suspicious of other leishmaniasis forms such as post kala-azar dermal leishmaniasis were excluded.

10.1371/journal.pntd.0007981.t001

###### Characteristics of the studies selected and test properties calculated after creating a 2 x 2 table.

![](pntd.0007981.t001){#pntd.0007981.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                 Yr     Index Tests             PCR Sample               Reference\                                        TP       FP       FN       TN       Sensitivity\     Specificity\     PPV %\           NPV %\           Accuracy %\      Study type     Control Group                                                  Species/origin                                          Target     Primers                                                 Amplicons size\
                                                                                    Standard [^a^](#t001fn004){ref-type="table-fn"}                                       (95% CI)         (95% CI)         (95% CI)         (95% CI)         (95% CI)                                                                                                                                                                                                                  (bp)
  ------------------------- ------ ----------------------- ------------------------ ------------------------------------------------- -------- -------- -------- -------- ---------------- ---------------- ---------------- ---------------- ---------------- -------------- -------------------------------------------------------------- ------------------------------------------------------- ---------- ------------------------------------------------------- ---------------------------------------------
  Gunaratna et al.          2018   SpeedXtract-RPA         Punch biopsy, SSS, FNA   A                                                 **61**   **0**    **32**   **57**   65.59\           100\             100\             64.04\           78.67\           Consecutive    NA                                                             *L*. *donovani*                                         kDNA       FP3/RP3                                                 160
                                                                                                                                                                          (55.02--75.14)   (93.74--100)     (94.13--100)     (53.18--73.95)   (71.24--84.93)                                                                                                                                                                                                            

  León CM et al.            2018   LAMP                    Smears                   A                                                 **36**   **4**    **0**    **10**   100\             71.43\           90\              100\             92\              Consecutive    NA                                                             Unknown                                                 18S rRNA   F3;B3;FIP;BIP                                           \<120[^c^](#t001fn006){ref-type="table-fn"}
                                                                                                                                                                          (90.26--100)     (41.90--91.61)   (76.34--97.21)   (69.15--100)     (80.77--97.78)                                                                                                                                                                                                            

  Koltas et al (a)          2016   kDNA-PCR                Smears                   A                                                 **30**   **11**   **0**    **31**   100\             73.81\           73.17\           100\             84.72\           Consecutive    NA                                                             *L*. *tropica; L*. *infantum; L*.*major*                kDNA       13A/13B                                                 120
                                                                                                                                                                          (88.43--100)     (57.96--86.14)   (57.06--85.78)   (88.78--100)     (74.31--92.12)                                                                                                                                                                                                            

  Koltas et al (b)          2016   SSU rRNA-PCR            Smears                   A                                                 **30**   **8**    **0**    **34**   100\             80.95\           78.95\           100\             88.89\           Consecutive    NA                                                             *L*. *tropica; L*. *infantum; L*.*major*                SSU rRNA   R221/R332                                               603
                                                                                                                                                                          (88.43--100)     (65.88--91.40)   (62.68--90.44)   (89.72--100)     (79.28--95.08)                                                                                                                                                                                                            

  Koltas et al (c)          2016   ITS2-PCR                Smears                   A                                                 **30**   **4**    **0**    **38**   100\             90.48\           88.24\           100\             94.44\           Consecutive    NA                                                             *L*. *tropica; L*. *infantum; L*.*major*                ITS2       L5.8SR/LISTV                                            700
                                                                                                                                                                          (88.43--100)     (77.38--97.34)   (72.55--96.70)   (90.75--100)     (86.38--98.47)                                                                                                                                                                                                            

  Koltas et al (d)          2016   ITS1-PCR                Smears                   A                                                 **29**   **0**    **1**    **42**   96.67\           100\             100\             97.67\           98.61\           Consecutive    NA                                                             *L*. *tropica; L*. *infantum; L*.*major*                ITS1       L58S/LITSR                                              320
                                                                                                                                                                          (82.78--99.92)   (91.59--100)     (88.06--100)     (87.71--99.94)   (92.50--99.97)                                                                                                                                                                                                            

  Koltas et al (e)          2016   ME-PCR                  Smears                   A                                                 **27**   **0**    **3**    **42**   90\              100\             100\             93.33\           95.83\           Consecutive    NA                                                             *L*. *tropica; L*. *infantum; L*.*major*                ME         FME/RME                                                 450
                                                                                                                                                                          (73.47--97.89)   (91.59--100)     (87.23--100)     (81.73--98.60)   (88.30--99.13)                                                                                                                                                                                                            

  Koltas et al (f)          2016   HSP70-PCR               Smears                   A                                                 **26**   **0**    **4**    **42**   86.67\           100\             100\             91.30\           94.44\           Consecutive    NA                                                             *L*. *tropica; L*. *infantum; L*.*major*                HSP70      HSP70sen/HSP70ant                                       1422
                                                                                                                                                                          (69.28--96.24)   (91.59--100)     (86.77--100)     (79.21--97.58)   (86.38--98.47)                                                                                                                                                                                                            

  Abd El-Salam et al.       2014   kDNA PCR                Smears                   A                                                 **53**   **46**   **8**    **6**    86.89\           11.54\           53.54\           42.86\           52.21\           Consecutive    NA                                                             *L*. *tropica*                                          kDNA       kDNA-Fw/kDNA-Rv[^b^](#t001fn005){ref-type="table-fn"}   186
                                                                                                                                                                          (75.78--94.16)   (4.35--23.44)    (43.23--63.62)   (17.66--71.14)   (42.61--61.70)                                                                                                                                                                                                            

  Eroglu et al. (a)         2014   Real-time PCR           Smears                   A                                                 **40**   **26**   **2**    **36**   95.24\           58.06\           60.60\           94.74\           73.08\           Consecutive    NA                                                             *L*. *tropica; L*. *infantum; L*.*major*                ITS1       LITSR/L5.8S                                             300--350
                                                                                                                                                                          (83.84--99.42)   (44.85--70.49)   (47.81--72.42)   (82.25--99.36)   (63.49--81.31)                                                                                                                                                                                                            

  Eroglu et al. (b)         2014   PCR                     Smears                   A                                                 **39**   **24**   **3**    **38**   92.86\           61.29\           61.90\           92.68\           74.04\           Consecutive    NA                                                             *L*. *tropica; L*. *infantum; L*.*major*                kDNA       13A/13B                                                 120
                                                                                                                                                                          (80.52--98.50)   (48.07--73.40)   (48.80--73.85)   (80.08--98.46)   (64.52--82.14)                                                                                                                                                                                                            

  Adams et al. (a)          2014   Qiagen (qPCR)           Swab                     B                                                 **78**   **4**    **2**    **21**   97.50\           84\              95.12\           91.30\           94.29\           Consecutive    NA                                                             *L*. *panamensis*                                       18S rDNA   rDNA-Fw/rDNA-Rv[^b^](#t001fn005){ref-type="table-fn"}   61
                                                                                                                                                                          (91.26--99.70)   (63.92--95.46)   (87.98--98.66)   (71.96--98.93)   (87.98--97.87)                                                                                                                                                                                                            

  Adams et al. (b)          2014   Isohelix (qPCR)         Swab                     B                                                 **74**   **4**    **6**    **21**   92.50\           84\              94.87\           77.78\           90.48\           Consecutive    NA                                                             *L*. *panamensis*                                       18S rDNA   rDNA-Fw/rDNA-Rv[^b^](#t001fn005){ref-type="table-fn"}   61
                                                                                                                                                                          (84.39--97.20)   (63.92--95.46)   (87.39--98.59)   (57.74--91.38)   (83.18--95.34)                                                                                                                                                                                                            

  Adams et al. (c)          2014   Qiagen (qPCR)           Aspirate                 B                                                 **64**   **2**    **16**   **23**   80\              92\              96.97\           58.97\           82.86\           Consecutive    NA                                                             *L*. *panamensis*                                       18S rDNA   rDNA-Fw/rDNA-Rv[^b^](#t001fn005){ref-type="table-fn"}   61
                                                                                                                                                                          (69.56--88.11)   (73.97--99.02)   (89.48--99.63)   (42.10--74.43)   (74.27--89.51)                                                                                                                                                                                                            

  Adams et al. (d)          2014   Boil/Spin (qPCR)        Aspirate                 B                                                 **49**   **1**    **31**   **24**   61.25\           96\              98\              43.64\           69.52\           Consecutive    NA                                                             *L*. *panamensis*                                       18S rDNA   rDNA-Fw/rDNA-Rv[^b^](#t001fn005){ref-type="table-fn"}   61
                                                                                                                                                                          (49.70--71.94)   (79.65--99.90)   (89.35--99.95)   (30.30--57.68)   (59.78--78.13)                                                                                                                                                                                                            

  El-Beshbishy et al. (a)   2013   kDNA PCR (seminested)   Skin biopsies            B                                                 **24**   **3**    **2**    **5**    92.31\           62.50\           88.89\           71.43\           85.29\           Consecutive    NA                                                             *L*. *major; L*.*tropica*                               kDNA       kDNA-Fw/kDNA-Rv[^b^](#t001fn005){ref-type="table-fn"}   757
                                                                                                                                                                          (74.87--99.05)   (24.49--91.48)   (70.84--97.65)   (29.04--96.33)   (68.94--95.05)                                                                                                                                                                                                            

  El-Beshbishy et al. (b)   2013   ITS1-PCR                Skin biopsies            B                                                 **18**   **0**    **8**    **8**    69.23\           100\             100\             50\              76.47\           Consecutive    NA                                                             *L*. *major; L*.*tropica*                               ITS1       LITSR/L5.8S                                             321
                                                                                                                                                                          (48.21--85.67)   (63.06--100)     (81.47--100)     (24.65--75.35)   (58.83--89.25)                                                                                                                                                                                                            

  Marco et al.              2012   PS-PCR                  Smears                   A                                                 **36**   **3**    **8**    **15**   81.82\           83.33\           92.31\           65.22\           82.26\           Case-control   non-ATL cases                                                  *L*. *braziliensis; L*. *guyanensis; L*. *panamensis*   PS         V1/V2; M1/M2                                            168 ; 700
                                                                                                                                                                          (67.29--91.80)   (58.58--96.42)   (79.13--98.38)   (42.73--83.62)   (70.47--90.80)                                                                                                                                                                                                            

  Khosravi et al.           2012   Real-time PCR           Skin biopsies            B                                                 **67**   **13**   **1**    **19**   98.53\           59.38\           83.75\           95\              86\              Consecutive    NA                                                             *L*. *major; L*.*tropica*                               TRYP       TRYP-F/TRYP-R                                           91
                                                                                                                                                                          (92.07--99.96)   (40.64--76.30)   (73.82--91.05)   (75.13--99.87)   (77.63--92.13)                                                                                                                                                                                                            

  Meymandi et al.           2009   Real-time PCR           Smears                   A                                                 **30**   **2**    **0**    **14**   100\             87.50\           93.75\           100\             95.65\           Case-control   Individuals clinically suspected but without Leishman bodies   Unknown                                                 kDNA       13A/13B                                                 120
                                                                                                                                                                          (88.43--100)     (61.65--98.45)   (79.19--99.23)   (76.84--100)     (85.16--99.47)                                                                                                                                                                                                            

  Lemrani et al.            2009   SSU rRNA-PCR            Skin biopsies            B                                                 **11**   **0**    **2**    **5**    84.62\           100\             100\             71.43\           88.89\           Case-control   Patients with other skin diseases similar to CL                *L*. *infantum; L*. *tropica; L*. *major*               SSU rRNA   R221/R332                                               650
                                                                                                                                                                          (54.55--98.08)   (47.82--100)     (71.51--100)     (29.04--96.33)   (65.29--98.62)                                                                                                                                                                                                            

  Kumar et al. (a)          2007   ITS1-PCR                Skin biopsies            B                                                 **24**   **0**    **5**    **3**    82.76\           100\             100\             37.5\            84.38\           Consecutive    NA                                                             *L*.*tropica*                                           ITS1       LITSR/L5.8S                                             300--350
                                                                                                                                                                          (64.23--94.15)   (29.24--100)     (85.75--100)     (8.52--75.51)    (67.21--94.72)                                                                                                                                                                                                            

  Kumar et al. (b)          2007   kDNA PCR                Skin biopsies            B                                                 **28**   **1**    **1**    **2**    96.55\           66.67\           96.55\           66.67\           93.75\           Consecutive    NA                                                             *L*.*tropica*                                           kDNA       Uni21/Lmj4                                              850; 650
                                                                                                                                                                          (82.24--99.91)   (9.43--99.16)    (82.24--99.91)   (9.43--99.16)    (79.19--99.23)                                                                                                                                                                                                            

  Al-Jawabreh et al.        2006   ITS1-PCR                Smears                   A                                                 **52**   **0**    **8**    **45**   86.67\           100\             100\             84.91\           92.38\           Case-control   Healthy volunteers                                             *L*.*major; L*.*tropica*                                ITS1       LITSR/L5.8S                                             319--335
                                                                                                                                                                          (75.41--94.06)   (92.13--100)     (93.15--100)     (72.41--93.25)   (85.54--96.65)                                                                                                                                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TP: true positives; FP: false positives; FN: false negatives; TN: true negatives; CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value.

RPA: recombinase polymerase amplification; LAMP: Loop-mediated isothermal amplification; kDNA: kinetoplast DNA; SSU rRNA: small subunit rRNA; ITS: internal transcribed spacer; ME: mini exon; HSP70: heat-shock protein; PCR: polymerase chain reaction; qPCR: quantitative PCR; PS-PCR: polymorphism-specific PCR; SSS: slit skin smear; FNA: fine needle aspirate; NA: not applicable; TRYP: Tryparedoxim peroxidase gene.

Publication with more than one amplification method were subdivided.

^a^ Standard A, Direct Microscopic; Standard B, Direct microscopic and/or Culture.

^b^ The author did not identify the primers in the article.

^c^ Based on the place where the primers hybridize, but amplicons vary depending on the number of loops that are formed.

Analysis of the selected papers {#sec009}
-------------------------------

Two of the authors screened the titles and abstracts identified through the search strategy (SR- Professor of Immunology and LEM-PhD candidate student) and selected those studies potentially relevant for this review. For all relevant articles, the full text version was read to determine the presence of the inclusion criteria defined previously. Two independent reviewers read the full text articles (CM-Professor of Molecular Biology and LEM-PhD candidate student). In case of disagreement in any of the phases of evaluation, a third reviewer was consulted for the final decision (SR-Professor of Immunology).

A set of standard data from each study was collected using a data extraction form; two reviewers performed a pilot test with the initial form using 3 of the included publications; the data extraction form was modified and improved according to the information derived from the pilot test. In the case of studies where only one subgroup of participants was eligible, such as studies where different types of reference tests are analyzed simultaneously, only the data of the analysis comparing the reference standard defined previously were extracted.

Two reviewers independently extracted the data and completed the predefined data extraction form (CM and LEM), any disagreements were resolved through the discussion with a third reviewer (SR), and the extracted data included general information such as reference, study location, index tests, reference standard, sample, study type, control group, and any another relevant information.

We evaluated the methodological quality of the included studies using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies). This tool is designed to assess the quality of primary diagnostic accuracy studies; consist of 4 key domains that discuss patient selection, index test, reference standard, and flow of patients through the study and timing of the index tests and reference standard (flow and timing); it is not designed to replace the data extraction process but complement the data extraction process of a systematic review. The researchers involved in the data extraction process were trained in the use of the QUADAS-2 tool \[[@pntd.0007981.ref008]\].

Data extraction and quality assessment were done independently by two reviewers (CM and LEM). Any discrepancies were resolved by consulting (SR). For 10% of the included studies, data extraction was also done by (SR). The decision regarding which studies would be included in the meta-analysis was primarily resolved using criteria related to the test methodology.

Anticipated sources of heterogeneity {#sec010}
------------------------------------

First, the selected papers were separated according to the reference standard used (direct microscopic test alone or in combination with culture) to define diseased and non-diseased subjects. Secondly, the type of PCR sample analyzed, study design, polymerase chain reaction target, size of the amplicons (pb), primes were considered. The DNA extraction methods that used commercial kits or phenol-extraction techniques were considered similar for human tissue samples that were stored in filter paper, paraffin embedded or frozen \[[@pntd.0007981.ref009]\]; in addition, the studies that used primers that amplify multiple copy genes were considered similar too \[[@pntd.0007981.ref009]\].

Searching to avoid heterogeneity among diagnostic test accuracy (DTA) studies, was focused on selecting a more homogeneous set of studies, however, heterogeneity is great among DTA studies and it is often difficult to strictly control biases. In order to achieve accurate review results, we used a first subgroup analysis that included studies that used exclusively the direct microscopic test as a reference standard. A second subgroup analysis was done with those studies where the reference standard included both direct microscopic test and/or culture but with comparable or similar methodologies.

Statistical analysis {#sec011}
--------------------

For all studies, estimates of sensitivity, specificity, positive and negative predictive value and 95% confidence intervals (CI) were expressed in forest plots in Review Manager version 5.3. We therefore investigated sources of heterogeneity by adding the following covariates to the mixed-effects logistic regression model: (i) the index tests, (ii) PCR sample, (iii) the study design, (iv) the reference standard and (v) the target gene (single or multicopy gene) using the command *xtmelogit* in STATA version 14. A covariate was assumed to have a significant effect on the estimates of sensitivity and specificity and thus to explain some of the heterogeneity in the studies included in meta-analysis if the *P* value was \< 0.05. We used two methods of meta-analyzing diagnostic accuracy data, which are statistically rigorous: the hierarchical summary receiver operating characteristic (HSROC) model \[[@pntd.0007981.ref010]\] and the bivariate logit-normal random-effects meta-analysis model \[[@pntd.0007981.ref011]\] to obtain a summary estimate of sensitivity and specificity, statistical analysis using *xtmelogit* in STATA version 14. Diagnostic accuracies between various readout methods for PCR (index tests), PCR samples, the study design and reference standard, were compared using Chi-square test with the programme STATA version 14.

Results {#sec012}
=======

Included studies {#sec013}
----------------

The electronic search yielded 142 results, 42 of which were taken forward to read the full text ([Fig 1](#pntd.0007981.g001){ref-type="fig"}). Articles were excluded at this stage due to (i) articles not available, (ii) not in the field of interest, (iii) use of an inappropriate reference standard, and (iv) inability to complete a 2-by-2 contingency table. A total of 13 articles were included in the systematic review \[[@pntd.0007981.ref005],[@pntd.0007981.ref012]--[@pntd.0007981.ref023]\] while data of 12 articles were included in the meta-analysis. Data of 1 article were not considered in the meta-analysis because they did not fit the respective subgroups for molecular method and/or sample type. Data extracted by a third reviewer as a quality assurance procedure was in agreements with the data extracted by the primary reviewers.

![Flow chart of included studies.](pntd.0007981.g001){#pntd.0007981.g001}

In the included studies, the index tests assessed were RPA (*n* = 1), LAMP (*n* = 1), conventional PCR (*n* = 14), real-time PCR (*n* = 3), qPCR (*n* = 4), PS-PCR (*n* = 1). Studies performing DNA extraction from smears (*n* = 13), SSS (slit skin smear) (*n* = 1), FNA (fine needle aspirate) (*n* = 1), punch biopsy (*n* = 1), swab (*n* = 2), aspirate (*n* = 2), skin biopsies (*n* = 6).

Quality assessment of study reports {#sec014}
-----------------------------------

Although we may choose to restrict the primary analysis to include only studies at low risk of bias or with low concern about applicability for either all or specified domains, we considered that is often preferable to review all relevant evidence and then investigate possible sources of heterogeneity. The results of quality assessment with the QUADAS-2 are summarized in terms of risk of bias and concerns regarding applicability for all included studies ([Fig 2](#pntd.0007981.g002){ref-type="fig"}). Of the 13 studies included, 4 were case-control studies, which resulted in a considerable proportion of studies having high risk of bias and high concern regarding applicability in the domain of patient selection. Respect to if could the conduct or interpretation of the index test have introduced bias, did raise problems in a large proportion of studies 85% (11/13), however there were no concerns regarding applicability in all the studies for this domain. A reference standard with unclear risk of bias was used in approximately 85% of the studies (11/13); even so, the target condition, as defined by the reference standard, was applicable to our review in all the studies. In 10 out of 13 studies, the patient's flow could have introduced bias; there was no details about that the results of the index test and reference standard were collected on the same patients at the same time.

![QUADAS-2 results showing risk of bias and applicability concerns of the studies selected.](pntd.0007981.g002){#pntd.0007981.g002}

Diagnostic accuracy of molecular tests and analysis of heterogeneity {#sec015}
--------------------------------------------------------------------

The 13 articles included 24 separate studies, that mean that more than one index test evaluated per article, for these 24 studies 2-by-2 contingency tables could be completed. Sensitivities ranged from 61% to 100%, and specificities ranged from 11% to 100% ([Table 1](#pntd.0007981.t001){ref-type="table"}). A coupled forest plot of sensitivity and specificity of PCR are shown in [Fig 3](#pntd.0007981.g003){ref-type="fig"}. Since it is important to take into account the type of sample used to diagnose CL, we decided that this analysis would be about the type of sampling procedure used; in this order, the summary HSROC curve for PCR in smear sample, reference standard A and case control and consecutive studies are show in [Fig 4A](#pntd.0007981.g004){ref-type="fig"}, and the HSROC curve for PCR in aspirate, skin biopsies and swab, reference standard B and case control and consecutive studies are show in [Fig 4B](#pntd.0007981.g004){ref-type="fig"}. There was no statistically significant difference in accuracy (sensitivity and specificity) between the various readout methods for PCR (LAMP, conventional PCR, real-time PCR, qPCR, PS-PCR), allowing the results to be pooled in the analysis (P value 0.469; 95% CI: -.613--1.331). There was no also statistically significant differences in accuracy between smears, SSS, FNA, punch biopsy, swab, aspirate and skin biopsies samples (P value 0.058; 95% CI: -.015-.940). Similarly, there was no statistically significant difference in accuracy between consecutive and case-control studies (P value 0.610; 95% CI: -.707--1.205). There was no statistically significant differences in accuracy between reference standard A and B (P value 0.537; 95% CI: -1.047--0.545) and there was no statistically significant differences in accuracy between multi and single copy target genes (P value 0.884; 95% CI: -0.974--0.839). When the results of the case-control studies were compared with those of the consecutive studies, which used as a reference standard direct microscopic test, no difference for sensitivity and specificity was found. The sensitivity and specificity in the studies which used as a reference standard direct microscopic and/or culture was slightly lower than in the studies that used reference standard test alone ([Table 2](#pntd.0007981.t002){ref-type="table"}).

![Couplet forest plots of the studies selected in Review Manager 5.3.](pntd.0007981.g003){#pntd.0007981.g003}

![HSROC curve for PCR.\
**A.** In smear sample, reference standard A, case control and consecutive studies combined. Circles represent estimates of individual primary studies, and square indicates summary points of sensitivity and specificity. The circled region around the solid square represent the 95% CI region around the summary estimate. HSROC curve is obtained using command "metandiplot" in STATA version 14. **B.** In skin biopsies and aspirate samples, reference standard B and case control and consecutive studies combined. Circles represent estimates of individual primary studies, and square indicates summary points of sensitivity and specificity. The circled region around the solid square represent the 95% CI region around the summary estimate. HSROC curve is obtained using command "metandiplot" in STATA version 14.](pntd.0007981.g004){#pntd.0007981.g004}

10.1371/journal.pntd.0007981.t002

###### Summary estimates for PCR[^a^](#t002fn001){ref-type="table-fn"}.

![](pntd.0007981.t002){#pntd.0007981.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Test and sample type                                                             Reference standard[^b^](#t002fn002){ref-type="table-fn"}   No. of articles\                                      Pooled sensitivity\                              Pooled specificity (95% CI)[^d^](#t002fn004){ref-type="table-fn"}
                                                                                                                                              (No. studies)[^c^](#t002fn003){ref-type="table-fn"}   (95% CI)[^d^](#t002fn004){ref-type="table-fn"}   
  -------------------------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------ -------------------------------------------------------------------
  Case-control and consecutive studies combined                                                                                                                                                                                                      

      PCR smears[^e^](#t002fn005){ref-type="table-fn"}                             A                                                          5(10)                                                 0.93\                                            0.95\
                                                                                                                                                                                                    (0.87--0.96)                                     (0.68--0.99)

      PCR smears[^f^](#t002fn006){ref-type="table-fn"}                             A                                                          7(13)                                                 0.95\                                            0.91\
                                                                                                                                                                                                    (0.90--0.98)                                     (0.70--0.98)

  Consecutive studies                                                                                                                                                                                                                                

      PCR smears[^e^](#t002fn005){ref-type="table-fn"}                             A                                                          3(8)                                                  0.95\                                            0.93\
                                                                                                                                                                                                    (0.88--0.98)                                     (0.56--0.99)

      PCR smears[^f^](#t002fn006){ref-type="table-fn"}                             A                                                          4(10)                                                 0.96\                                            0.88\
                                                                                                                                                                                                    (0.90--0.98)                                     (0.59--0.98)

  Case-control and consecutive studies combined                                                                                                                                                                                                      

      PCR aspirate, skin biopsies and swab[^e^](#t002fn005){ref-type="table-fn"}   B                                                          4(9)                                                  0.88\                                            0.90\
                                                                                                                                                                                                    (0.77--0.93)                                     (0.80--0.95)

      PCR aspirate, skin biopsies and swab[^f^](#t002fn006){ref-type="table-fn"}   B                                                          5(10)                                                 0.90\                                            0.87\
                                                                                                                                                                                                    (0.80--0.95)                                     (0.76--0.94)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Statistical analysis in STATA version 14, is obtained using command \"xtmelogit\".

^b^ Standard A, Direct Microscopic; Standard B, Direct microscopic and/or Culture.

^c^ The 12 articles included 23 separate studies, that means that more one index test evaluated per article.

^d^ CI, confidence interval.

^e^ All readout methods of the index test except LAMP and Real-time PCR

^f^ All readout methods of the index test without exception

The summary estimates for sensitivity and specificity for both "All readout methods of the index test except LAMP and Real-time PCR" and "All readout methods of the index test without exception" on smears samples (general population) were high; however, the estimates were lower in aspirate, skin biopsies and swab samples in general population. The consecutive studies still show high summary sensitivities of 0.95 for smears (All readout methods of the index test except LAMP and Real-time PCR) and 0.96 (All readout methods of the index test without exception), but specificities are lower at 0.93 and 0.88, respectively and their CI are wider.

Further analysis was confined to the smears samples in the studies, which used as a reference standard the direct microscopic test, given, that the subgroup that used aspired, skin biopsies and swab samples in studies with reference standard direct microscopic and/or culture were too small to perform an analysis of heterogeneity. Furthermore, there was no big differences in accuracy between studies that used direct microscopy and, studies that used direct microscopy and/or culture as a reference standard.

Since there is no recommended method to assess the publication bias and that no inferences can be made regarding the presence or absence of this bias, in this systematic review and meta-analysis was not assessed the publication bias. Nevertheless, we recognize that this bias is a serious problem which can affect the validity and generalization of conclusions.

Discussion {#sec016}
==========

Molecular test with high quality sensitivity has been widely used for diagnosing of CL. PCR is suitable when there are atypical lesion of CL and few numbers of parasites, or when the microscopic method is negative, molecular diagnosis appears to be the solution to the short-falls on traditional diagnostic methods. In this systematic review, we analyzed and summarized data from diagnostic accuracy studies of molecular test in the diagnosis of CL. After to identify all relevant studies from the available literature, we were able to assess the accuracy of PCR tests in smears, aspirate, skin biopsies and swab.

The finding the high estimates for sensitivity and specificity on smears samples and low estimates on aspirate, skin biopsies and swab samples in general population, allows us to believe that a simple smears sample would suffice instead of taking more invasive skin biopsies or aspirate samples. This finding is important from patient's point of view because highlighting the use of non-invasive sampling procedures, which generate greater stigmatization in patients due to the permanent scars.

The low specificities found in all readout methods of the index test, can be attributed, in part, to the fact that the controls in case-control studies are often healthy persons, whereas controls in consecutive studies are in fact suspected patients; variation in the controls were one of the most frequent points of heterogeneity among the studies \[[@pntd.0007981.ref008]\]. The high number of positive PCR tests in suspected patients with a negative reference standard may be explained by a proportion of the false positives being true positive when we take into consideration that the reference standard for CL is imperfect and that the sensitivity of PCR test is superior to the reference standard.

Consecutive studies better reflect the diagnosis situation and are thus of higher methodological quality than case-control studies \[[@pntd.0007981.ref023]\]. We therefore recommend that future diagnostic accuracy studies should use a consecutive design to determine whether our findings about specificity are reproducible and to obtain valid estimates.

This meta-analysis shows that the molecular methods are very sensitive tools for the detection of *Leishmania* parasites in smears samples instead of invasive skin biopsies or aspirate samples, for which, we found lower pooled estimated for sensitivity, as well as specificity. Though due to limited data, it was not possible to provide summary estimates for consecutive studies and case-control studies separately on aspirate, skin biopsies and swab samples. Regarding to the future diagnostic accuracy studies, we highlight the fact of leave out the case-control studies to avoid that diagnostic accuracy being overestimated and consider the results for PCR in simple smears sample such as the most accurate method for the diagnosis of CL instead more invasive samples \[[@pntd.0007981.ref024]\].

The results of this systematic review and meta-analysis have important implications in public health because the diagnostic of CL through direct microscopic test is a highly operator dependent method. This means that the results depend of skills of who performs the test; therefore, the molecular methods can help to avoid this bias and permit obtain improve diagnostics and ensure the adequate treatments in patients. It is also important that the sensitivity of the molecular methods for the diagnosis of CL be high in a simple smear samples instead of invasive samples, because the scars left by the disease already stigmatize the patients and obtaining a sample through invasive methods would be useless.

Conclusions {#sec017}
-----------

Results suggest that the molecular methods are very sensitive tools for the detection of *Leishmania* parasites in smears samples instead of invasive skin biopsies or aspirate samples, we no found statistically differences between the accuracy in smears, aspirate, skin biopsies or swabs samples. Therefore, we consider that a simple smear sample run by PCR instead more invasive sample is enough to obtain a positive diagnosis of CL. The results for PCR in all samples type confirm previous reports that consider PCR as the most accurate method for the diagnosis of CL.

Limitations {#sec018}
-----------

Many studies in our meta-analysis suffer from poor quality. Thirty-one percent of the included studies had a case-control study type and this design is reputed to introduce selection bias, as the cases are confirmed patients and the controls are healthy volunteers or patients with other skin diseases similar to CL. Imperfect reference standard bias is an important issue in diagnostic accuracy studies. In the case of CL, there is a risk of underestimates the specificity of a new test when comparing it to current methods that have low sensitivity and high specificity, such as reference standard.

QUADAS-2 assessment showed that 85% of the studies, the conduct or interpretation of the index test and the reference standard could have introduced bias when judged against these definitions.

The analysis of heterogeneity done or all studies combined did not show a significant difference between studies that used standard A, reference standard and studies that used a composite reference standard B, reference standard and/or culture. Neither were significant differences between the readout methods of the index test. Nevertheless, subgroups were analyzed separately: "all readout methods of the index test except LAMP and real-time PCR" and "all readout methods of the index test without exception".

The lack of standardization is another limitation when you want to compare diagnostic accuracy studies for molecular tools. These different protocols are evidenced in the [Table 1](#pntd.0007981.t001){ref-type="table"}. An additional problem encountered during all process of studies selection, data extraction, and quality assessment of the included studies, were incomplete reporting of studies. This is due to the not use of the STARD guidelines for reporting diagnostic accuracy studies.

Supporting information {#sec019}
======================

###### PRISMA-DTA for abstract checklist.

(DOCX)

###### 

Click here for additional data file.

###### PRISMA-DTA checklist.

(DOCX)

###### 

Click here for additional data file.
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Dear Professor Robledo:

Thank you very much for submitting your manuscript \"Test accuracy of polymerase chain reaction methods against conventional diagnostic techniques for Cutaneous Leishmaniasis (CL) in patients with clinical or epidemiological suspicion of CL: systematic review and meta-analysis.\" (\#PNTD-D-19-01036) for review by PLOS Neglected Tropical Diseases. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

When you are ready to resubmit, please be prepared to upload the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed (uploaded as a \"Revised Article with Changes Highlighted\" file); the other a clean version (uploaded as the article file).

\(3\) If available, a striking still image (a new image if one is available or an existing one from within your manuscript). If your manuscript is accepted for publication, this image may be featured on our website. Images should ideally be high resolution, eye-catching, single panel images; where one is available, please use \'add file\' at the time of resubmission and select \'striking image\' as the file type.

Please provide a short caption, including credits, uploaded as a separate \"Other\" file. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License at <http://journals.plos.org/plosntds/s/content-license> (NOTE: we cannot publish copyrighted images).

\(4\) If applicable, we encourage you to add a list of accession numbers/ID numbers for genes and proteins mentioned in the text (these should be listed as a paragraph at the end of the manuscript). You can supply accession numbers for any database, so long as the database is publicly accessible and stable. Examples include LocusLink and SwissProt.

\(5\) To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-methods>

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

We hope to receive your revised manuscript by Dec 20 2019 11:59PM. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email.

To submit a revision, go to <https://www.editorialmanager.com/pntd/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.
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Mitali Chatterjee

Guest Editor
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Alain Debrabant

Deputy Editor
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer \#1: The objective of the study is clearly stated and the study design is well described. However, the statistical methods used are not fully discribed. For example, what statistical method was used to test differences in the accuracies.

Reviewer \#2: The manuscript by Mesa et al presents a systematic review and meta-analysis regarding the test accuracy of polymerase chain reaction methods against conventional diagnostic

techniques for Cutaneous Leishmaniasis (CL) in patients with clinical or

epidemiological suspicion of CL. The authors have used both case control and consecutive studies for this purpose as the studies pertaining to this are very limited and pooled analysis of all the molecular diagnostic methods including PCR, LAMP, RPA, real time PCR were carried out.

The review protocol adopted for analysis followed by authors is standard. In conclusion from 12/13 studies from which the data could be extracted the conclusion was drawn that the molecular methods have high sensitivity and specificity in all the readout methods, and the accuracy of test is similar in smears, aspirate, skin biopsies or swabs samples. In conclusion, authors recommend that a simple smears sample run by PCR instead more invasive samples is enough to obtain a positive diagnosis of CL.

Comments:

1\. For heterogeneity analysis gold standard test were a. direct microscopy and b. microscopy and or culture. However, for generation of HSROC authors have again used gold standard A and B and here it indicates the sample type A. smear B. invasive sample.

For clarity and comparative representation fig 3 and fig 4 can be merged in to one as 3 a and 3b and it may be indicated that this analysis is about the type of sampling procedure used. As it is one of the main findings and should be emphasized from patients point of view highlighting the use of non invasive sampling procedure.

2\. Line 300-302, it may be rephrased to give clear directions for the future diagnostic accuracy studies to be carried out, instead of stating that future studies will support the findings of this study.

3\. The language is not lucid at several places and interpretation become difficult, it may be improved. eg line 264; 278; 287

Reviewer \#3: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? No

-Is the study design appropriate to address the stated objectives? Yes

-Is the population clearly described and appropriate for the hypothesis being tested? Yes

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? Not applicable

-Were correct statistical analysis used to support conclusions? Yes

-Are there concerns about ethical or regulatory requirements being met? No

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: Tables 1 and 2 are not available for review

line 235-236: There is no pooled estimate in Figure 2.

line 239-241: The authors wrote here and other places that \"there were no significant differences in the accuracies between various methods.\" What statistical analysis was used to test these difference.

line 278-279: Revise the statement.

line 287: Do you mean: There was, however, \"no significant\" or \"a non-significant\" difference\...

Although the results in this study are well discussed, the author almost failed to provide justifications for their findings. What are the implications for low accuracies of these tests? What are the implications?

Reviewer \#2: (No Response)

Reviewer \#3: -Does the analysis presented match the analysis plan? Yes, but not well presented

-Are the results clearly and completely presented? No

-Are the figures (Tables, Images) of sufficient quality for clarity? Yes.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: -Are the conclusions supported by the data presented?: No conclusions in the main manuscript!

-Are the limitations of analysis clearly described?: Somewhat

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?: Somewhat

-Is public health relevance addressed?: Not adequately

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: (No Response)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: Abstract:

1\. Writes confidence interval (CI) in full only the first time used and use CI subsequently.

2\. May I suggest the authors separate \"Methods\" and \"Results\"

Introduction:

3\. Page 3 line 74-75: Provide reference for this statement \"The evolution time of the lesion and the previous use of treatments may also interfere with the sensitivity of the direct methods.\"

Materials and methods

line 115: Remove the inverted question mark

line 152: I was wondering why the authors removed all studies where a 2 by 2 contingency table cannot be created?

line 211: You mean \"\<0.05\"?

Reviewer \#2: (No Response)

Reviewer \#3: This paper systematically reviews and meta-analyses the sensitivity and specificity of PCR-based tests when compared to direct microscopy (+/- isolation of promastigotes in cultures) at diagnosing cutaneous leishmaniasis. It is generally sound in its methods but the writing needs more work in my opinion. Here are some comments/suggestions:

General and/or methodological comment

Abstract:

The objective and the primary conclusion don't align. This should be corrected.

Introduction:

Perhaps the author could consider shortening it, and should clearly describe the concepts of the clinical workflow in the target condition, prior tests (like clinical suspicion), index test and comparator tests, and intended role of the index test in the clinical workflow.

No objective statement in the introduction section.

Materials and methods

Why wasn't PRISMA-DTA not followed? This is the usual reporting standard for diagnostic systematic reviews

Was any grey literature source searched? Were conference abstracts excluded?

Search terms: I would argue including concepts of direct tests and humans restricts the search term unnecessarily (\"direct exam\" OR \"direct test\" OR \"direct tests\" OR \"direct microscopy\" OR smear)) AND Humans. How many studies were lost due to inclusion of these terms in the search term with Boolean concept AND? How many of them were relevant?

\- Analysis of the heterogeneity of the papers: suggest also considering the inclusion of treated patients and study location as sources of heterogeneity between studies.

\- "Heterogeneity was assessed using Cochran's Q test as well as Higgins' I2 statistic": no results eventually provided. I would suggest excluding them altogether

Study inclusion: a number of studies have double counting of patients. Authors should be transparent about this as this means that this results in a faulty over-assumption about the variability by the statistical models.

\- reconsider denoting direct test as the "gold standard". It isn't, indeed PCR based methods are generally thought to have better accuracy. Instead, consider using "reference standard"

Analysis:

"Statistical analysis and meta-analysis.": sounds odd together. Suggest just use either "Statistical analysis" or "meta-analysis"

-Suggest mentioning the model before the covariates.

\- Were the covariates entered together or individually? Since this was the formal way that the authors tested for heterogeneity, in my opinion, the former section should be called "anticipated sources of heterogeneity" and the actual assessment of heterogeneity detailed under statistical analysis.

\- "heterogeneity in the studies included in meta-analysis if the P value was 0.05...": authors do not mention any P value in the results.

\- while there is no recommended method to test for publication bias, a statement regarding this should be included. \[I would also suggest considering inspection of funnel plot (diagnostic odds ratio vs sample size) and including this as a post-hoc analysis in supplementary material. I understand no inferences can be made regarding the presence or absence of publication bias though.\]

Results:

"Study characteristics" usually connotes study design. Instead authors list PCR methods and source of biological material. Consider reorganizing.

"Quality assessment of study reports" logically comes before the main results (and so perhaps should the associated figures). Consider reorganizing

Diagnostic accuracy of molecular tests and analysis of heterogeneity: consider adopting a more narrative style rather than just pointing out tables and figures.

Table 2, as presented, is very confusing. If it represents subgroup analyses, then one would intuitively think that the subgroups would be consecutively recruited vs Case-control (indeed, as stated in the analysis section), and not the combined

categories.

Figure 1. Consider detailing the "inappropriate gold standard"s since 15 studies were excluded because of this criterion.

Why is PRISMA flow chart also included as supplementary material?

Discussion:

Generally poorly organized.

Page 10, 283-290: these are results.

Page 10, 289-290: is this analysis post-hoc? it is not mentioned in the methods

No conclusion

Other stylistic issues:

Abstract:

Background: "....PubMed, EMBASE and LILACS": this should be part of the Methodology

Methodology/Principal findings:

Suggest excluding \"This is to be expected, because the controls in case-control studies are often healthy persons, whereas controls in consecutive studies are in fact suspected patients.\"

The following sentence is grammatically incorrect: "Estimates were lower on aspirates, skin biopsies and swab samples in general population 0.90 (95% confidence interval \[CI\], 0.80 to 0.95) and 0.87 (95% confidence interval \[CI\], 0.76 to 0.94) for sensitivity and specificity, respectively."

"More than 30 Leishmania species are recognized, of which 20 are considered infective for humans and other mammals." This sentence should be referenced.

Other examples of grammatical errors or stylistic concerns include but not limited to:

" significant differences between the readout method of the index test, however, subgroups were analyzed separately: "all readout methods of the index test except LAMP and real-time PCR" and "all readout methods of the index test without exception".

"The lack of standardization is another limitation when you want to compare diagnostic accuracy studies for molecular tools."

Page 3, 70-71

Page 4, 95

Page 7, 196-198

Page 9, 264-265

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

###### 

Submitted filename: Review PNTD CL metaanalysis.docx

###### 

Click here for additional data file.

10.1371/journal.pntd.0007981.r002

Author response to Decision Letter 0

7 Nov 2019

###### 

Submitted filename: Response to Reviewers.pdf

###### 

Click here for additional data file.

10.1371/journal.pntd.0007981.r003

Decision Letter 1

Debrabant

Alain

Deputy Editor

Chatterjee

Mitali

Guest Editor

© 2020 Debrabant, Chatterjee

2020

Debrabant, Chatterjee

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

9 Dec 2019

Dear Professor Robledo,

We are pleased to inform you that your manuscript, \"Test accuracy of polymerase chain reaction methods against conventional diagnostic techniques for Cutaneous Leishmaniasis (CL) in patients with clinical or epidemiological suspicion of CL: systematic review and meta-analysis.\", has been editorially accepted for publication at PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please note: your manuscript will not be scheduled for publication until you have made the required changes.

IMPORTANT NOTES

\* Copyediting and Author Proofs: To ensure prompt publication, your manuscript will NOT be subject to detailed copyediting and you will NOT receive a typeset proof for review. The corresponding author will have one final opportunity to correct any errors when sent the requests mentioned above. Please review this version of your manuscript for any errors.

\* If you or your institution will be preparing press materials for this manuscript, please inform our press team in advance at <plosntds@plos.org>. If you need to know your paper\'s publication date for media purposes, you must coordinate with our press team, and your manuscript will remain under a strict press embargo until the publication date and time. PLOS NTDs may choose to issue a press release for your article. If there is anything that the journal should know, please get in touch.

\*Now that your manuscript has been provisionally accepted, please log into EM and update your profile. Go to <http://www.editorialmanager.com/pntd>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

\*Note to LaTeX users only - Our staff will ask you to upload a TEX file in addition to the PDF before the paper can be sent to typesetting, so please carefully review our Latex Guidelines \[<http://www.plosntds.org/static/latexGuidelines.action>\] in the meantime.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Mitali Chatterjee

Guest Editor

PLOS Neglected Tropical Diseases

Alain Debrabant

Deputy Editor

PLOS Neglected Tropical Diseases
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Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#2: The objectives have been stated clearly now.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

**Results**

-Does the analysis presented match the analysis plan?
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